Independent report · Private Markets

Advent International and Yatharth Hospitals: Equity and warrants at

September 17, 2026 · By Janvi

Yatharth Hospital · Image: Franchise India

Yatharth Hospital · Image: Franchise India

Independent report content

ISSUERYatharth Hospital & Trauma Care Services Limited (NSE: YATHARTH, BSE: 543950), Delhi NCR hospital chain · IPO July 2023 · promoters Ajay Kumar Tyagi and family and Kapil Kumar hold 55.80% (June 2026)
INVESTORAdvent International through Rasmalai Limited (Cyprus) · Advent AUM above US$109bn (30 June 2026), 55+ healthcare investments
DEAL₹3,150 Cr (about US$328.5m) primary capital · 13,026,516 equity shares (₹1,283.33 Cr) plus 18,947,664 warrants (₹1,866.67 Cr), all at ₹985.17
PAYMENTWarrants: 25% upfront (₹246.29), 75% (₹738.88) on exercise · Rupeia: about ₹1,750 Cr at signing, about ₹1,400 Cr later
STAKE24.87% fully diluted (24.9% rounded) after all warrants convert · Tyagi family stays largest shareholder
IMPLIED MULTIPLESPre-money enterprise value about ₹9,400 Cr: about 26.7x LTM EBITDA, 6.3x LTM revenue, 52.6x LTM profit (Rupeia calculations)
STATUS AT 7 NOV 2026Announced; shareholder and regulatory approvals required; EGM reported for 15 October 2026; completion not confirmed in sources read
THE ACCESS POINT Yatharth Hospital is listed on NSE and BSE, so its shares trade openly. Advent is paying ₹985.17 a share through a preferential allotment, which individuals cannot join. The 3 November 2026 NSE close of ₹981.85 is within 0.3% of that price.

Executive decision summary

THE BOTTOM LINEAdvent has agreed to put ₹3,150 crore into Yatharth Hospitals for a 24.87% stake, a large outside investment in a listed Delhi NCR hospital chain that the Tyagi family still controls. The money is not all in the bank on day one: about ₹1,750 crore arrives through equity and the upfront quarter of the warrants, and about ₹1,400 crore only when Advent exercises the rest. The price of ₹985.17 values the company at roughly ₹9,400 crore of enterprise value before the money, or about 27 times trailing EBITDA, in the middle of listed hospital peers. The Tyagi family stays the largest shareholder and no control changes hands. The bet is that Yatharth can grow from about 2,555 beds to more than 5,000 in three years while holding EBITDA margins near 24–25%, and that the newer hospitals scale as Faridabad and Agra have.
WHICH INVESTORThe deal fits you IF you want a listed, profitable, fast-growing hospital chain (Q2 FY27 revenue up 52%) whose largest outside investor is a global private-equity firm paying the market price, and you accept about 27x trailing EBITDA. Wait IF you need the shareholder vote, regulatory approvals and warrant exercise timetable confirmed first, or if you are concerned about the rise in depreciation (up 75%) and finance cost (₹8.3 crore against ₹0.3 crore a year ago).
COMFORT FITEquity plus warrants = a down payment and a layaway plan. Advent pays for part now and keeps the right, not the duty, to pay the balance at the same price later. A 24.87% stake = just under the line. Indian takeover rules trigger an open offer at 25%; Advent stays below it, which also explains why the Tyagi family keeps the wheel. The Aster talks in August = the other bidder at the door. Reports said Advent and Aster were both negotiating for control; the outcome was a minority deal at the market price. Yatharth = a franchise of new wings. Four newer hospitals now supply 28% of revenue, and the older ones are growing 24% a year as well.
THE RUPEIA NUMBER₹985.17. The price per share Advent will pay, about 3.3 times the ₹300 IPO price of July 2023 and within 0.3% of the 3 November 2026 close.

1 CLAIM REGISTER: EVIDENCE GRADING

A = government, regulator, exchange or statutory filing. B = company or manager release or website. C = independent press. D = third-party database, blog or aggregator.

ClaimSourceGradeRupeia assessment
₹3,150 Cr primary investment for 24.9% (24.87% fully diluted), announced 17 Sep 2026Advent press release; exchange filing as reported by Sahi, Digital Health News, MultibaggBEstablished
13,026,516 equity shares and 18,947,664 warrants at ₹985.17; warrants 25% upfrontExchange filing as reported by Sahi and MultibaggAEstablished; one outlet gives 31,974,177 shares, three fewer than the sum
Investor vehicle Rasmalai Limited, CyprusSahi; MultibaggCReported; Advent release names only Advent
Tyagi family remains largest shareholder; promoters 55.80% (June 2026)Advent release; Business Today; Kotak NeoBEstablished
Authorised capital ₹115 Cr to ₹150 Cr; EGM on 15 Oct 2026Sahi; Multibagg; Entrepreneur India (date)CDate from one outlet only
FY26 revenue ₹1,207.2 Cr, EBITDA ₹292.1 Cr, PAT ₹170.3 CrCompany results as reported by Whalesbook and QuartrBEstablished
Q2 FY27 revenue ₹431.4 Cr, EBITDA ₹102 Cr, PAT ₹48.5 Cr, occupancy 72%Investor presentation as reported by Multibagg, Angel OneBEstablished
Aster DM and Advent in talks for control (28 Aug 2026); Yatharth denied being partyKotak Neo; Angel One citing press reportsCReported; denial undated
Share price record ₹1,065–1,067 (17 Sep) and ₹1,183.15 (18 Sep)Business Today; Reuters via DealStreetAsiaCSources differ on the 17 Sep high
Net debt or net cash of ₹116 Cr at 31 Mar 2026Whalesbook (net debt); Quartr and Sahi (net cash)CConflict preserved

2 THE DEAL IN ONE PAGE

TermDetailSource
IssuerYatharth Hospital & Trauma Care Services Limited; NSE: YATHARTH, BSE: 543950Advent release
InvestorAdvent International, via Rasmalai Limited (Cyprus-incorporated)Sahi; Multibagg
InstrumentPreferential issue of equity shares and convertible share warrantsExchange filing via Multibagg
Equity sharesUp to 13,026,516 at ₹985.17 = ₹1,283.33 CrSahi; Multibagg
WarrantsUp to 18,947,664 at ₹985.17 = ₹1,866.67 Cr; 25% (₹246.29) upfront; ₹738.88 on exerciseMultibagg
Total₹3,150 Cr, about US$328.5m (Reuters); implied rate about ₹95.9 per US$Advent release; DealStreetAsia
Stake24.87% post-issue, fully diluted including granted ESOPsSahi; Multibagg
Authorised capitalTo rise from ₹115 Cr to ₹150 CrSahi; Multibagg
GovernanceNon-executive board representation for AdventOmnicuris
ApprovalsShareholders (EGM) and customary regulatory approvalsSahi; Multibagg; Advent release
Use of fundsNetwork expansion; more than 5,000 beds in three years; Gurugram 250-bed hospitalSahi

Yatharth Tyagi, Whole-time Director, said in the Advent release that the investment "marks a pivotal milestone in our journey". Pankaj Patwari, Managing Director at Advent, said: "We are pleased to partner with the Yatharth family". Atin Jain, Director at Advent, also spoke of partnering with the management team. Sources read do not name banks or law firms, a lock-in period, the warrant exercise window, or the SEBI pricing basis for the preferential issue.

3 WHY A PREFERENTIAL ISSUE: PRIMARY CAPITAL VERSUS A CONTROL SALE

The Advent investment is a primary transaction: Yatharth issues new shares and warrants and receives the money. No promoter sells a share. That separates it from the transaction the August press reports described, in which Advent or Aster would have bought control from the Tyagi family. In a control sale the money goes to the sellers and the takeover code requires an open offer to public shareholders, which Kotak Neo and Angel One put at a further 26%.

FeaturePreferential issue (this deal)Control purchase (reported in August)
Who receives the moneyThe company, for expansionThe selling promoters
Effect on share countRises by about 33% once warrants convertNo change
Promoter holdingFalls from 55.80% to roughly 42% fully diluted (Rupeia estimate)Falls sharply or ends
Open offer to publicNot described; stake kept below 25%Further 26% reported as mandatory
BoardNon-executive seat for Advent (Omnicuris)Control of the board
Company cashUp by ₹1,750 Cr at allotmentUnchanged
RUPEIA READ For the Tyagi family the preferential route trades dilution for continuity: they keep operating control and the company gets the capital, instead of the family receiving cash and handing over the business. For public shareholders it adds a well-funded growth plan and a new top-tier holder, at the cost of a one-third larger share count. The August reports suggest control sale was at least discussed by third parties; Yatharth denied being party to such talks.

4 WHEN THE MONEY ARRIVES: A CASH-FLOW SCHEDULE

The headline ₹3,150 crore is the sum of two instruments with different payment dates. Rupeia computed the split from the published per-share amounts.

ComponentCalculationAmount (₹ crore)When
Equity shares13,026,516 × ₹985.171,283.33On allotment after approvals
Warrants, upfront 25%18,947,664 × ₹246.29466.67On allotment
Cash at signing, total1,283.33 + 466.671,750.00On allotment
Warrants, balance 75%18,947,664 × ₹738.881,400.00On exercise; window not stated
Total1,750.00 + 1,400.003,150.00
RUPEIA CALCULATION Exactly 55.6% of the headline (1,750 / 3,150) arrives on allotment and 44.4% (1,400 / 3,150) later. Against Yatharth's Q2 FY27 cash and bank balance of about ₹429 crore, the upfront ₹1,750 crore is about 4.1 times existing cash. The deferred ₹1,400 crore is Advent's option: under the usual terms of Indian warrant issues, the upfront amount is lost if the warrants lapse, so Advent will exercise only if the shares merit the same ₹985.17. The company cannot treat the second half as certain capital.

5 WHO ADVENT IS

Advent International had assets under management above US$109 billion at 30 June 2026 and says it has made more than 55 healthcare investments worldwide. In India it has been mainly active in pharmaceuticals, with holdings reported in Bharat Serums and Vaccines and Cohance Lifesciences. Digital Health News says Advent is led in India by Shweta Jalan. Its hospital history in India is thin: Kotak Neo describes CARE Hospitals in 2012 as its only previous hospital investment, and Digital Health News says it exited in 2016 by selling to the UAE-based Abraaj Group. In 2024 it made a ₹2,475 crore equity investment in Apollo 24|7, the digital health business of Apollo Hospitals.

Advent India healthcare transactionYearPublished detailSource
CARE Hospitals2012Investment; exit in 2016 to Abraaj Group (Digital Health News); Blackstone later took control in 2023 (PipelineRoad)Kotak Neo; Digital Health News; PipelineRoad
Apollo 24|72024₹2,475 Cr equity investmentDigital Health News
Bharat Serums and Vaccines; Cohance Lifesciencesn/aOther Indian holdings namedOmnicuris
Yatharth Hospitals2026₹3,150 Cr for 24.87%Advent release
RUPEIA READ Advent is not new to Indian healthcare but is new to running hospital capacity in India for the second time. Its first hospital deal ended with a sale in four years. The Yatharth structure, a minority stake with warrants and board representation but no control, is a different design from a majority buy-out, and suits an investor who wants growth exposure and a defined exit route through the stock market.

6 COMPANY OVERVIEW: FROM NOIDA EXTENSION TO NINE HOSPITALS

Yatharth Hospital & Trauma Care Services was founded in 2008 according to PipelineRoad, citing Private Equity Wire, and now runs nine multi-speciality hospitals with about 2,800 operational beds and announced capacity of about 3,250 beds (Advent release and Reuters). Digital Health News lists the locations as Noida, Greater Noida, Noida Extension, Greater Faridabad, Model Town in New Delhi, Faridabad, Jhansi-Orchha in Madhya Pradesh and Agra, with a 250-bed Gurugram hospital planned. Multibagg's Q2 FY27 coverage gives total bed capacity of 2,555 and 1,820 operational census beds, so bed counts depend on definition (see below).

Hospital or sitePublished detailSource
Noida Extension26% of Q2 FY27 revenueMultibagg
Greater Noida23% of Q2 FY27 revenueMultibagg
Noida16% of Q2 FY27 revenueMultibagg
Faridabad Sector-20400 beds; ₹40 Cr in Q2 FY27 (9%); ARPOB about ₹40,000; EBITDA-positiveMultibagg
Model Town, New Delhi300 beds; ₹26 Cr (6%); ARPOB about ₹50,000; EBITDA breakeven expected H2 FY27Multibagg
Agra250 beds; ₹20 Cr (5%); ARPOB about ₹33,000; EBITDA-positiveMultibagg
Jhansi-Orchha305 beds acquired by 2023; loss-making in FY23 per IPO coverage5paisa
Gurugram Sector 40250 beds under construction; 100% stake bought for ₹100 Cr; opening April 2027 to H1 FY28Multibagg; Whalesbook; Sahi

Promoters Ajay Kumar Tyagi and family, with Kapil Kumar, held 55.80% in June 2026. Yatharth Tyagi is Whole-time Director. Employees number about 7,500 (Multiples).

7 TIMELINE: 2008–2026

DateMilestone
2008Company founded (PipelineRoad citing Private Equity Wire)
26–28 Jul 2023IPO at ₹285–300; ₹686 Cr issue; subscribed 37.28 times
7 Aug 2023Listing on NSE
FY24Revenue ₹670.5 Cr (+29%) on FY23 ₹520.3 Cr
25 May 2026Shares fall 7.18% to ₹801 after Q4 FY26 results
3 Jun 2026FY26 revenue ₹1,207.2 Cr (+36%) reported
Jun 2026Gurugram Sector 40 hospital acquired for ₹100 Cr
10 Aug 2026Maiden interim dividend ₹0.50 a share (₹4.82 Cr); ESOP Scheme 2026 of 250,000 shares
28 Aug 2026Reports that Advent and Aster DM are negotiating for control; Yatharth denies being party to sale talks
14 Sep 2026Board meeting intimation on growth plans and fundraising
17 Sep 2026Definitive agreement with Advent; shares hit record high
18 Sep 2026Shares up 20.38% over two days to ₹1,183.15 intraday
15 Oct 2026EGM reported for the preferential issue (Entrepreneur India)
3–4 Nov 2026Q2 FY27 results: revenue ₹431.4 Cr (+52%), EBITDA ₹102 Cr, PAT ₹48.5 Cr; shares close ₹981.85 on 3 Nov

8 THE IPO AND WHAT THE LISTING PRICE TELLS US

Yatharth listed on 7 August 2023 after a ₹686 crore IPO between 26 and 28 July at a price band of ₹285–300. The issue combined a fresh issue of up to ₹490 crore and an offer for sale of up to 65.51 lakh shares (up to ₹196.55 crore) by promoter-group entities. Anchor investors put in ₹206 crore (68.65 lakh shares at ₹300 to 18 funds), including Goldman Sachs (Singapore), SBI Life, Max Life, Kotak Mahindra Life, ICICI Prudential, HDFC, Nippon India and Aditya Birla Sun Life funds. Lead managers were Intensive Fiscal Services, Ambit and IIFL Securities. The objects included debt repayment, capital expenditure at Noida and Greater Noida, and acquisitions.

DayQIBNIIRetailTotal
26 Jul 20230.26x1.84x1.33x1.14x
27 Jul 20230.29x6.08x3.53x3.15x
28 Jul 202386.37x38.62x8.65x37.28x
RUPEIA CALCULATION Advent's ₹985.17 is 3.28 times the IPO price of ₹300 (985.17 / 300). Over about 3.1 years from listing to the agreement that is roughly 46% a year (3.28^(1/3.12)). On the 5paisa figures the company had 1,405 beds at the IPO and now has 2,555 total, so beds grew about 1.8 times while revenue grew from ₹520 crore (FY23) to ₹1,207 crore (FY26), about 2.3 times, and the price rose 3.3 times. The market has paid for faster-than-bed growth in revenue per bed and for expansion still to come.

9 FINANCIAL FORENSICS: FY23 TO Q2 FY27

₹ croreRevenueEBITDAEBITDA marginPATSource
FY23520.3n/sn/sn/sWhalesbook
FY24670.5 (+29%)n/sn/sn/sWhalesbook
FY25About 888 (implied)n/sn/sAbout 131 (implied)Rupeia: 1,207.2 / 1.36; 170.3 / 1.30
FY261,207.2 (+36%)292.1 (+30%)24.2%170.3 (+30%)Whalesbook; Quartr
Q1 FY26259.266.025.4%42.0Sahi
Q2 FY26283.068.124.1%41.3Multibagg
Q3 FY26321.4n/sn/s43.1Business Today
Q4 FY26341.6 (+47%)79.9 (+37%)23.4%44.7 (+15%)Business Today; Quartr
Q1 FY27392.7 (+51%)91.7 (+39%)23.3%45.4 (+8%)Sahi
Q2 FY27431.4 (+52%)102.0 (+50%)23.6%48.5 (+17%)Multibagg; Angel One
H1 FY27824.1 (+52%)193.7 (Rupeia sum)23.5%93.9 (+12.7%)Multibagg

FY25 figures are not stated in any source read and are inferred from the reported FY26 growth rates (n/s means not stated). Angel One reports Q2 FY27 total income of ₹436.44 crore, about ₹5 crore above revenue from operations, which Multibagg attributes to other income. Quarterly numbers do not sum exactly to the annual figures (revenue ₹1,205.2 crore against ₹1,207.2 crore).

Balance sheet and cashFigureSource
Gross debt, 31 Mar 2026₹230 CrWhalesbook
Net debt or net cash, 31 Mar 2026₹116 Cr net debt (Whalesbook) or ₹116 Cr net cash (Quartr, Sahi)Conflict
Cash and bank balances, Q2 FY27₹428.90 CrAngel One
FY26 operating cash flow₹286.6 Cr (98% cash conversion)Business Today
Debtor days, FY26112; target 90–95 by FY27Whalesbook; Quartr
Q2 FY27 depreciation / finance cost₹33.1 Cr (+75%) / ₹8.3 Cr (vs ₹0.3 Cr)Multibagg
RUPEIA READ Revenue is doubling in two years but profit is growing far slower: Q2 FY27 revenue rose 52% and PAT only 17%, because depreciation rose 75% and finance cost went from almost nothing to ₹8.3 crore as new hospitals were built and funded. EBITDA margin has drifted from 25.4% (Q1 FY26) to 23.6% because newer hospitals carry ramp-up costs; the company says ex-ramp-up margin is about 28%. The Advent money pays for more of the same growth, so the tension between revenue and profit growth will continue for several quarters.

10 OPERATING METRICS: BEDS, OCCUPANCY AND REVENUE PER BED

MetricQ2 FY26Q2 FY27Source
Total bed capacity2,3052,555Multibagg
Operational census beds1,5351,820Multibagg
Occupancy66%72%Multibagg
ARPOB (₹ per occupied bed per day)32,42635,948 (+11%)Multibagg; Angel One
Average length of stay4.0 days3.3 daysMultibagg
In-patient volume22,00036,000Multibagg
Out-patient volume108,000158,000Multibagg
IPD revenue / OPD revenue₹251 Cr / ₹32 Cr₹373.9 Cr / ₹57.5 CrMultibagg
Revenue from newer hospitals11%28% (₹120.5 Cr)Multibagg

Bed counts conflict across sources: "over 3,200 beds" (Whalesbook), "over 2,800 beds across nine hospitals" with 3,255 planned (Angel One), and 2,555 total capacity (Multibagg). The differences reflect operational, licensed and announced beds. The payer mix shows government schemes at about 35% of revenue (Whalesbook, Sahi), with a target of under 30% (Sahi) or 25% (Sahi); Faridabad Sector-20 is "more than 90%" cash and TPA business.

RUPEIA CALCULATION Revenue per total bed in Q2 FY27 is ₹431.4 crore / 2,555 = ₹16.9 lakh a quarter, or ₹67.5 lakh annualised. Against the company's capex of ₹75–80 lakh per bed for the next 1,800 beds, a new bed repays its capex in revenue terms in about 1.1–1.2 years at the group average, before operating costs and ramp-up. At a 24% EBITDA margin the payback on capex is about 4.6–4.9 years (78 / (67.5 × 0.24)) for a bed at the group average.

11 WHAT THE FY27 GUIDANCE IMPLIES FOR THE SECOND HALF

Management guided to FY27 revenue growth above FY26's 36% and EBITDA margin of 24–25% (Quartr, Sahi). Rupeia compared that with the first half already reported.

ItemCalculationResult
FY27 revenue at 36% growth (floor of guidance)1,207.2 × 1.36About ₹1,642 Cr
H1 FY27 revenueReported₹824.1 Cr
H2 FY27 revenue needed1,642 − 824.1About ₹818 Cr
H2 revenue at the Q2 FY27 run-rate431.4 × 2About ₹863 Cr
FY27 EBITDA at 24–25% of ₹1,642 Cr1,642 × 0.24 / 0.25₹394–411 Cr
H1 FY27 EBITDA91.7 + 102.0₹193.7 Cr
H2 EBITDA needed394–411 − 193.7₹200–217 Cr
H2 EBITDA at the Q2 FY27 run-rate102 × 2₹204 Cr
RUPEIA READ The guidance floor is roughly what the company is already running at. Holding the Q2 FY27 quarterly revenue and EBITDA flat for two more quarters would deliver about ₹1,687 crore of revenue (824.1 + 863) and ₹398 crore of EBITDA (193.7 + 204), inside the guided range. Guidance therefore asks for no further growth in the second half. The share price, which has already returned to the deal price, suggests the market wants more than the floor.

12 IMPLIED VALUATION: WHAT ₹985.17 MEANS

Rupeia reconstructed the implied capitalisation from the published numbers. Advent's 31,974,180 shares equal 24.87% of the fully diluted count, so the fully diluted count after the deal is about 128.56 million shares and the pre-deal fully diluted count about 96.59 million. The market capitalisation on 27 August 2026 was ₹9,462 crore at ₹973.05 (Kotak Neo), which implies about 97.2 million shares, in line with that count.

ItemCalculationResult
Fully diluted shares after deal31,974,180 / 0.2487About 128.56 million
Pre-deal shares128.56 − 31.97About 96.59 million
Pre-money equity value96.59 million × ₹985.17About ₹9,516 Cr
Post-money equity value128.56 million × ₹985.17About ₹12,665 Cr
Enterprise value before money (net cash ₹116 Cr)9,516 − 116About ₹9,400 Cr
LTM revenue at Q2 FY271,207.2 − 542.3 + 824.1₹1,489 Cr
LTM EBITDA at Q2 FY27292.1 − 134.1 + 193.7₹351.7 Cr
LTM PAT at Q2 FY27170.3 − 83.29 + 93.88₹180.9 Cr
EV / LTM revenue9,400 / 1,489About 6.3x
EV / LTM EBITDA9,400 / 351.7About 26.7x
Price / LTM earnings9,516 / 180.9About 52.6x
EV / FY26 EBITDA9,400 / 292.1About 32.2x
EV per total bed (2,555)9,400 / 2,555About ₹3.7 Cr
EV per census bed (1,820)9,400 / 1,820About ₹5.2 Cr
RUPEIA READ At about 27 times trailing EBITDA Yatharth is priced between Narayana Health (about 23x) and the large generalists (about 39x on The Core's August 2026 data), and in line with Multiples' own 27.3x LTM. The enterprise value per bed of ₹3.7 crore is about 4.7 times the company's own replacement cost of ₹75–80 lakh a bed, which is the premium the market and Advent are paying for an operating, ramped-up, profitable network rather than a construction pipeline. Whether the premium holds depends on newer hospitals reaching the margin of the older ones.

13 DILUTION AND CONTROL: WHAT HAPPENS TO THE TYAGI FAMILY

ItemCalculation or factResult
Promoter holding, June 2026Reported55.80%
Promoter shares (assuming about 96.6m outstanding)55.80% × 96.6 millionAbout 53.9 million
Promoter share of fully diluted post-deal count53.9 / 128.56About 41.9% (Rupeia estimate)
Increase in share count from Advent shares31.97 / 96.59+33.1%
Advent stakeFully diluted24.87%
Open-offer threshold in the takeover codeGeneral rule: 25%Advent is 0.13 points below

The company says the Tyagi family "will remain the Company's largest shareholder" (Business Today, quoting Yatharth). Multibagg calls the deal a minority investment, not a change of control, with Rasmalai classified as a public shareholder. In the Aster story, Kotak Neo and Angel One reported that a control sale would trigger a mandatory open offer for a further 26%, potentially taking a buyer above 75%.

RUPEIA READ The 24.87% number is chosen, not accidental: it keeps Advent just under the 25% threshold of the takeover code, and the promoter family keeps roughly 42% on Rupeia's estimate after all warrants convert. Yatharth Tyagi's phrase "pivotal milestone" and the board seat describe a partner, not a buyer. If Advent later wanted more than 25%, the code would require an open offer to public shareholders, which would be a separate event.

14 WHAT THE DEAL MEANS FOR EARNINGS PER SHARE

New shares dilute earnings per share until the new capital earns a return. Rupeia estimated the effect from the trailing figures in the implied-valuation section.

ItemCalculationResult
LTM profit after taxFrom the Q2 FY27 build-up₹180.9 Cr
LTM earnings per share, before deal180.9 Cr / 96.59 millionAbout ₹18.7
LTM earnings per share, after all new shares, before new earnings180.9 Cr / 128.56 millionAbout ₹14.1
Mechanical dilution14.1 / 18.7 − 1About −24.9%
Extra profit needed to restore EPS180.9 × (128.56 / 96.59 − 1)About ₹59.9 Cr
Return on the ₹3,150 Cr needed to do so59.9 / 3,150About 1.9% after tax
Price to earnings at ₹985.17 on pre-deal EPS985.17 / 18.7About 52.6x
RUPEIA READ A 1.9% after-tax return on the new money is a low bar, and a hospital bed yielding the group-average EBITDA margin clears it easily once opened. The dilution is real only during the build-out: the new beds take two to three years to ramp, and warrant money is not invested until exercise. A reader should watch EPS growth, not only revenue growth, over FY27 and FY28.

15 THE ASTER STORY: A CONTROL SALE THAT BECAME A MINORITY DEAL

On 28 August 2026 Kotak Neo, citing people familiar with the matter, reported that Advent International and Aster DM Quality Care (backed by Blackstone and TPG) were negotiating for a controlling stake in Yatharth. Kotak Neo wrote that Yatharth "has denied being party to any sale discussions" and that Blackstone said it was "neither evaluating a deal nor part of any sale process". Angel One, citing the Economic Times, said due diligence was "nearing completion" with "no certainty of a deal", and that Aster preferred a cash transaction to a stock-based merger. Digital Health News had earlier reported talks for Advent to raise up to ₹3,000 crore through primary issuance in two tranches, taking 20–24%. Aster DM was described as having about 40 facilities in 27 cities and about 10,800 beds, with a target of 15,000 by FY29.

DateShare price eventSource
27 Aug 2026Close ₹973.05; market cap ₹9,462 CrKotak Neo
28 Aug 2026Up 4.65% to ₹1,010.20 at 10:22 am; close ₹969.50 (−0.36%)Kotak Neo; Angel One
17 Sep 2026Up as much as 8.4–8.6% to a record ₹1,065–1,067Business Today; Reuters
18 Sep 2026Up as much as 10.53% to ₹1,183.15; +20.38% over two daysBusiness Today
3 Nov 2026NSE close ₹981.85 (+4.63%)Angel One
RUPEIA CALCULATION At ₹1,183.15 the stock traded 20.1% above Advent's price (1,183.15 / 985.17); at the 3 November close of ₹981.85 it was 0.3% below it. Advent's equity shares were therefore worth ₹1,279 crore against ₹1,283 crore cost on 3 November (13,026,516 × 981.85), roughly break-even. Investors who bought on the announcement spike are below their entry unless they bought below about ₹982.

16 STRATEGIC RATIONALE AND USE OF FUNDS

Yatharth says it will expand to more than 5,000 beds within three years and may reach it sooner (Sahi). Management put capex at ₹75–80 lakh per bed for the next 1,800 beds and about ₹1 crore per bed in Gurugram, targeting EBITDA margins of 24–25% in FY27 and revenue growth above FY26's 36%. Angel One quotes a reference to Advent capital supporting 7,000–8,000 beds.

Plan itemCalculationResult
New beds to reach 5,000 from 2,5555,000 − 2,5552,445 beds
Capex for 1,800 beds at ₹75–80 lakh1,800 × 0.75–0.80₹1,350–1,440 Cr
Capex for Gurugram 250 beds at about ₹1 Cr250 × 1About ₹250 Cr (company: ₹100 Cr purchase plus ₹100 Cr)
Capex for the remaining 645 beds at ₹78 lakh645 × 0.78About ₹503 Cr
Total capex to reach 5,000 beds1,395 + 200 + 503 (mid-point)About ₹2,100 Cr
Cash at signing plus Q2 cash1,750 + 429About ₹2,180 Cr
RUPEIA READ The upfront ₹1,750 crore plus existing cash of ₹429 crore covers roughly the entire capex needed to reach 5,000 beds on the company's own per-bed numbers, before operating cash flow of ₹287 crore a year. That makes the deferred ₹1,400 crore of warrants look like capacity for faster growth, acquisitions or the 7,000–8,000 bed ambition rather than a necessity. It also means Yatharth could in principle fund its stated plan with little debt, which helps the margin after finance cost.

17 APPROVALS AND REGULATORY PATH

StepWhat the sources sayStatus in sources read
Board approvalBoard met 17 Sep 2026 and approved the preferential issueDone
Increase in authorised capital₹115 Cr to ₹150 Cr; memorandum changeNeeds shareholder vote
Shareholder approval (special resolution)EGM reported for 15 Oct 2026Outcome not found
Stock exchange in-principle approvalNot statedNot stated
CCI or sector approvalsNot statedNot stated
SEBI takeover codeMinority stake; Rasmalai a public shareholderNo open offer described
Allotment and paymentEquity and upfront warrants on allotmentNot confirmed by 7 Nov 2026

Entrepreneur India says the transaction "has been approved by shareholders" while also saying the EGM was scheduled for 15 October; Sahi and Multibagg describe approvals as pending. Because the EGM outcome and allotment are not stated in any source read, this report treats the deal as signed and approved by the board but not shown as completed.

18 COMPARABLE DEALS AND PEER VALUATIONS

Company or dealEV/EBITDA or valueSource and date
Six large generalists (Apollo, Max, Fortis, Aster, Medanta, KIMS)About 39x average; Aster about 46x, KIMS about 43x, Max about 42xThe Core, 19 Aug 2026 (data 13 Aug)
Specialists (Dr Agarwal's, Rainbow, HCG)About 24–25xThe Core
Narayana HrudayalayaAbout 23xThe Core
Small regional chains (Kovai, Shalby, Indraprastha)About 14x, 13x and 11xThe Core
Yatharth at marketAbout 27.3x LTM EBITDA, 6.7x revenue, 49.5x earnings; EV about US$1.1bnMultiples.vc, 7 Nov 2026
Yatharth at Advent price (Rupeia)About 26.7x LTM EBITDA; 6.3x revenue; 52.6x earningsRupeia calculation
Apollo 24|7 (Advent, 2024)₹2,475 Cr equityDigital Health News
CARE Hospitals (Blackstone, 2023)Controlling stake; terms not stated in sources readPipelineRoad
Medicover India (KKR)US$1.4bn; terms not stated in sources readPipelineRoad
RUPEIA READ The Advent price sits at the lower end of the large-chain range and in the middle of the specialist and regional range: Yatharth is not priced like Max or Aster. That is consistent with a regional chain with a government-scheme share of about 35% of revenue. A PE investor can reasonably call that a growth multiple, and a public-market investor can call it full for a chain whose ex-ramp-up margin is 28% but reported margin is under 24%.

19 COMPETITION AND MARKET CONTEXT

ICRA's July 2026 update rated the Indian hospital sector outlook positive, with revenue growth of 13–15% and ARPOB growth of 6–8% projected for FY2027 and occupancy around 62–64%. Yatharth's occupancy of 72% and ARPOB growth of 11% are above those sector figures. The Core reports that the industry is adding about 34,000 beds by FY29 at over ₹40,000 crore, Aster DM is adding about 4,080 beds in two years, Rainbow is adding 2,500 beds, and Max plans 10,000 beds by FY30.

PeerCapacity or planSource
Aster DM Quality CareAbout 40 facilities, about 10,800 beds; target 15,000 by FY29Kotak Neo; Angel One
Max Healthcare10,000 beds by FY30; ₹6,000 Cr planned capexThe Core citing Business Today
Rainbow Children'sAdd 2,500 beds to reach 5,000 for about ₹2,200 CrThe Core
Manipal Hospitals49 hospitals, 12,600+ beds (2026)Aggregator
Yatharth2,555 beds now; 5,000+ in three yearsMultibagg; Sahi

20 RISK ANALYSIS: RED FLAG LEDGER & KILL CONDITIONS

Red flagEvidenceSeverityKill conditionWhat would resolve it
Completion riskEGM and regulatory approvals; no allotment confirmedMEDIUMShareholders reject or SEBI objectsAllotment announcement
Warrant optionality₹1,400 Cr (44%) payable only on exerciseMEDIUMShare price below ₹985.17 when exercise is dueExercise notices
Margin dilution from ramp-upEBITDA margin 25.4% to 23.6%; depreciation +75%MEDIUMMargin below 22% for two quartersFaridabad and Model Town reach breakeven
Government-scheme dependenceAbout 35% of revenueMEDIUMRate cuts or payment delaysMix target under 30%
Working capitalDebtor days 112MEDIUMDays rise above 120Target 90–95 by FY27
ValuationAbout 27x LTM EBITDA; 52.6x earningsMEDIUMGrowth slows below 30%Revenue growth above FY26's 36%
Bed-count ambiguity2,555, 2,800 and 3,200+ across sourcesLOWInvestor presentation redefines bedsUniform bed disclosure
Execution of 2,400+ bedsGurugram timing April 2027 to H1 FY28MEDIUMOpenings slip beyond FY28Opening on schedule

21 SCENARIO ANALYSIS: FY27 TO FY29

ScenarioWhat happensImplication
BullRevenue growth stays above 40%; newer hospitals reach ex-ramp-up margins near 28%; Advent exercises all warrants earlyMultiple holds near 27x on a larger EBITDA base; 5,000 beds reached ahead of plan
BaseRevenue grows 30–36%; margin stays 23–25%; warrants exercised on scheduleShare price tracks earnings growth; Advent exits through stock-market sales later
BearRamp-up drags margin below 22%; payment delays raise debtor days; share price falls below ₹985.17Advent does not exercise warrants; upfront ₹467 Cr is lost; growth capital shrinks

Scenarios are for discussion. They are not forecasts, use no unpublished company data and do not predict a share price.

22 INVESTOR CLASS ANALYSIS

For HNIs

Yatharth is a listed stock and can be held through a demat account. The Advent price of ₹985.17 is a useful reference, but the preferential allotment cannot be joined. Positions in a stock that moved 20% in two days should be sized for volatility.

For family offices

Family offices can follow the same logic as Advent through placements and block deals. The staged warrant structure is a template for a staged entry, which limits the capital committed before the company shows ramp-up results.

For institutions

Long-only and healthcare funds will compare the 27x multiple with sector peers and with Advent's buy-in price. The new capital also lowers the risk of a dilutive equity raise later.

For NRIs

NRIs can buy listed Indian shares through the portfolio investment scheme subject to RBI and FEMA limits for non-resident holdings.

23 COMFORT FIT: THE DECISION PAGE

If you want…Best fitWhyCaution
A profitable, growing listed hospital chain with a global PE partnerYATHARTHRevenue +52%, PAT positive, new hospitals reaching breakevenAbout 27x EBITDA; deal completion pending
A private hospital model at an early stageEVEN HEALTHCARE (Report 20)Salaried-doctor model; Khosla-backedLoss-making; unlisted
A larger, higher-multiple hospital exposureLarge listed chainsScale and liquidityAbout 39x EBITDA

24 THE EARLY SIGNAL: EVENTS TO WATCH

WhenEventWhy it matters
Q4 2026Allotment of shares and upfront warrantsConfirms the ₹1,750 Cr arrives
Q3 FY27 results (early 2027)Margin and depreciation trendShows whether ramp-up costs are peaking
H2 FY27Model Town EBITDA breakevenTest of the newer-hospital model
By April 2027 to H1 FY28Gurugram 250-bed openingHighest ARPOB site
2027–28Warrant exerciseWhether Advent pays the remaining ₹1,400 Cr

25 RUPEIA FINAL INDEPENDENT VIEW

Advent's ₹3,150 crore commitment is a significant endorsement of a regional hospital chain whose deal price is more than three times its IPO price and whose revenue nearly doubled between FY24 and FY26. The structure is careful: a minority stake just under the open-offer line, half the cash on day one and the rest at Advent's option, a price within a fraction of the market, and a Tyagi family that stays in charge. For Yatharth the deal means the funding for its plan to reach 5,000 beds is largely in hand.

What remains open is delivery. Margins have slipped as newer hospitals ramp, depreciation and finance cost are rising quickly, and the market price after the announcement spike has returned to the deal price. The case rests on the newer hospitals following Faridabad and Agra to profitability, and on revenue growth staying above the 36% of FY26.

THE RUPEIA NUMBER ₹1,750 crore: the cash Advent pays at allotment (equity ₹1,283 crore plus 25% of the warrants, ₹467 crore), 55.6% of the headline ₹3,150 crore.
RUPEIA VERDICT A well-structured minority investment at roughly the market price. The headline overstates the cash on day one, and the next signals are allotment, the margin trend and warrant exercise. This note offers no buy, sell or price view.

Frequently asked questions

How much is Advent investing in Yatharth Hospitals?

₹3,150 crore (about US$328.5 million) of primary capital, announced on 17 September 2026, for 24.9% (24.87% fully diluted) through Rasmalai Limited, a Cyprus-incorporated Advent vehicle.

At what price is Advent buying?

₹985.17 per equity share and per warrant. That is about 0.3% above the implied prior close of about ₹982 on 17 September (Rupeia derivation from Angel One) and 3.3 times the IPO price of ₹300.

Is the full ₹3,150 crore paid at once?

No. Equity of ₹1,283.33 crore is paid on allotment together with 25% of the warrant price (about ₹467 crore, Rupeia calculation). The remaining ₹1,400 crore is payable when Advent exercises its warrants.

Does Advent take control of Yatharth?

No. Advent gets a 24.87% fully diluted stake and non-executive board representation. The Tyagi family, which held 55.80% in June 2026, remains the largest shareholder.

What were the Aster DM reports?

On 28 August 2026 press reports said Advent and Aster DM Quality Care were negotiating for control. Yatharth denied being party to sale talks and Blackstone said it was not evaluating a deal.

What are Yatharth's latest results?

Q2 FY27 revenue was ₹431.4 crore (+52%), EBITDA ₹102 crore (+50%), PAT ₹48.5 crore (+17%) and occupancy 72%. FY26 revenue was ₹1,207.2 crore, EBITDA ₹292.1 crore and PAT ₹170.3 crore.

What valuation does the deal imply?

Rupeia estimates pre-money enterprise value of about ₹9,400 crore, or about 26.7 times trailing EBITDA, 6.3 times revenue and 52.6 times earnings. The company has not published such multiples.

What will the money be used for?

Expansion to more than 5,000 beds in three years, including a 250-bed Gurugram hospital. Management cites capex of ₹75–80 lakh per bed.

Has the deal closed?

Not confirmed in the sources read. It needs shareholder approval (EGM reported for 15 October 2026) and customary regulatory approvals.

Source log

Advent International: to invest ₹3,150 crore in Yatharth Hospitals for 24.9% stake

Sahi: Yatharth Hospitals secures ₹3,150-crore Advent investment

Digital Health News: Advent to invest ₹3,150 Cr in Yatharth Hospitals

Digital Health News: Yatharth Hospitals in talks with Advent

Entrepreneur India: Advent to invest US$328.5 Mn in Yatharth Hospital

Angel One: Yatharth Hospitals share price surges as Advent invests

DealStreetAsia: Advent to buy 25% in Yatharth Hospital for US$328.5 million

Multibagg: Yatharth Hospital okays ₹3,150 crore issue

InvestyWise: Yatharth Hospitals private equity investment secured

Omnicuris: Advent Yatharth Hospitals private equity investment

Business Today: Yatharth Hospital shares jump over 8% to record high

Business Today: Yatharth Hospital shares jump 20% in two days

Kotak Neo: Advent, Aster eye controlling stake in Yatharth Hospitals

Angel One: Aster DM, Advent in reported talks for controlling stake

PipelineRoad: Advent to invest US$328.5m for 24.9% stake in Yatharth

Whalesbook: Yatharth Hospital FY26 revenue surges 36% to ₹1,207 Cr

Business Today: Yatharth Hospital shares slip 7% after Q4 FY26 results

Quartr: Yatharth Hospital Q4 25/26 earnings summary

Multibagg: Yatharth Q2 revenue rises 52% as PAT growth slows to 17%

Multibagg: Yatharth new hospitals reach 28% of Q2 FY27 group revenue

Angel One: Yatharth Hospital share price gains after Q2 FY27 results

Sahi: Yatharth Hospital targets upwards of 24% EBITDA margin and ₹75-80 lakh capex per bed

Sahi: Yatharth Hospital expects to reach 5,000-bed capacity sooner

Multiples.vc: Yatharth Hospital valuation multiples

5paisa: Yatharth Hospital IPO

DT Next: Yatharth Hospital mops up ₹206 Cr from anchor investors

Outlook Business: Yatharth Hospital IPO price band ₹285-300

The Core: India's listed hospital chains valuation analysis

ICRA: Hospital sector, strong demand and ARPOB rise support FY2027 growth

DISCLAIMER This document is published strictly for informational, educational and academic record-keeping purposes. The publisher is not a SEBI Registered Investment Adviser (RIA) or Research Analyst (RA). It does not constitute personal investment advice, a financial recommendation, or an offer or solicitation to buy, sell or subscribe to any securities. Investments in the securities market are subject to market risks. Read all related documents carefully before investing.